AllQuantitative Report
Argus•May 05, 2021
Argus•May 05, 2021SUPN: Lowering target price to $32.00
Summary
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeActions
Download Full ReportRelated Reports
- CORT: Lowering target price to $18.00Apr 24, 2024 •
CORT
- JAZZ: Raising target price to $115.00Apr 24, 2024 •
JAZZ
- ANIP: What does Argus have to say about ANIP?Apr 24, 2024 •
ANIP
- IRWD: Raising target price to $9.00Apr 24, 2024 •
IRWD
- COLL: Rating increased to a BUYApr 24, 2024 •
COLL